The effect of Effervescent Magnesium tab in the hypomagnesemic pregnant women

Effect of Effervescent magnesium tab on the outcome of pregnancy in women who have hypomagnesemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015121925611N1

Enrollment

180

Registered

2016-01-25

Start date

2014-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Evaluation of outcomes of pregnancy in Effervescent magnesium tab consumers. other maternal disorder predominantly related to pregnancy

Interventions

Control group c: multimineral tab of alhavi company contains 100mg magnesium,1tab daily till delivery

Intervention 1: Intervention group A: 200mg effervescent magnesium tab once a day until 1 month +multi mineral tab of Alhavi company contains 100mg magnesium,1tab daily till the end of pregnancy. Inte

Treatment - Drugs

Intervention group A: 200mg effervescent magnesium tab once a day until 1 month +multi mineral tab of Alhavi company contains 100mg magnesium,1tab daily till the end of pregnancy

Intervention group B: multimineral tab of alhavi company contains 100mg magnesium,1tab daily till delivery

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1.have tendency to involve in this study and sign the agreement 2.single pregnancy 3.gestational age 12-14wks 4.no acute renal disease 5.hypomagnesemia in interventional group and normal magnesium 6.no history chronic HTN 7.no history of overt diabetes 8.no history of severe anemia 9.no history of diagnostic heart disease. 10.no anomaly inthis pregnancy and previous ones. 11.no use of cigrrate and alcohol. 12.no molar pregnancy 13.no acute pancreatitis Exclusion criteria: 1.discard the study. 2.inappropriate use of magnesium. 3.don't. Come for follow up. 4.interactable vomiting

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Intrauterine growth retardation. Timepoint: at delivery. Method of measurement: weight under10 percentile.;Weight of neonate. Timepoint: at delivery. Method of measurement: kilogram.;Preterm labor. Timepoint: at delivery. Method of measurement: labor before 37 weeks.;Pregnancy induced hypertension. Timepoint: HTN after 20th weeks gestational age with or without proteinuria. Method of measurement: mm Hg with manometer.;Gestational Diabetes. Timepoint: 26 to28. Method of measurement: oral gelocose challenge test (mg/dl).;Leg cramp. Timepoint: during pregnancy. Method of measurement: question.;Intra uterine fetal death. Timepoint: at delivery. Method of measurement: No fetal heart rate on sonography.;Apgar on 5 min. Timepoint: at delivery. Method of measurement: measure by Apgar scale.;Gestational age at delivery. Timepoint: at delivery. Method of measurement: gestational age.;Times of admission at hospital. Timepoint: at delivery. Method of measurement: question.;Maternal age at delivery. Timepoint: at delivery. Method of measurement: question.	—

Measure

Time frame

Intrauterine growth retardation. Timepoint: at delivery. Method of measurement: weight under10 percentile.;Weight of neonate. Timepoint: at delivery. Method of measurement: kilogram.;Preterm labor. Timepoint: at delivery. Method of measurement: labor before 37 weeks.;Pregnancy induced hypertension. Timepoint: HTN after 20th weeks gestational age with or without proteinuria. Method of measurement: mm Hg with manometer.;Gestational Diabetes. Timepoint: 26 to28. Method of measurement: oral gelocose challenge test (mg/dl).;Leg cramp. Timepoint: during pregnancy. Method of measurement: question.;Intra uterine fetal death. Timepoint: at delivery. Method of measurement: No fetal heart rate on sonography.;Apgar on 5 min. Timepoint: at delivery. Method of measurement: measure by Apgar scale.;Gestational age at delivery. Timepoint: at delivery. Method of measurement: gestational age.;Times of admission at hospital. Timepoint: at delivery. Method of measurement: question.;Maternal age at delivery. Timepoint: at delivery. Method of measurement: question.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Amal Tarjan

Isfahan University of Medical Science

A_tarjan@yahoo.com+98 316413161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026